<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37009515</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response.</ArticleTitle><Pagination><StartPage>1142172</StartPage><MedlinePgn>1142172</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1142172</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2023.1142172</ELocationID><Abstract><AbstractText>Recent reports have revealed that oncolytic viruses (OVs) play a significant role in cancer therapy. The infection of OVs such as oncolytic vaccinia virus (OVV), vesicular stomatitis virus (VSV), parvovirus, mammalian reovirus (MRV), human adenovirus, Newcastle disease virus (NDV), herpes simplex virus (HSV), avian reovirus (ARV), Orf virus (ORFV), inactivated Sendai virus (ISV), enterovirus, and coxsackievirus offer unique opportunities in immunotherapy through diverse and dynamic pathways. This mini-review focuses on the mechanisms of OVs-mediated virotherapy and their effects on immunogenic cell death (ICD), apoptosis, autophagy and regulation of the immune system.</AbstractText><CopyrightInformation>Copyright © 2023 Wu, Sun, Chen, Munir and Liu.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yi-Ying</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The iEGG and Animal Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Te-Kai</ForeName><Initials>TK</Initials><AffiliationInfo><Affiliation>Tsairder Boitechnology Co. Ltd., Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Ming-Shan</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munir</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biomedical and Life Sciences, Lancaster University, Lancashire, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hung-Jen</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Institute of Molecular Biology, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The iEGG and Animal Biotechnology Center, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ph.D Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079527" MajorTopicYN="N">Immunogenic Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">immune system</Keyword><Keyword MajorTopicYN="N">immunogenic cell death</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">oncolytic viruses</Keyword><Keyword MajorTopicYN="N">virotherapy</Keyword></KeywordList><CoiStatement>Author T-KS was employed by Tsairder Boitechnology Co. Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>3</Day><Hour>4</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37009515</ArticleId><ArticleId IdType="pmc">PMC10050605</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2023.1142172</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguirre-Hernández C., Maya-Pineda H., Millán J. S., Man Y. K. S., Lu Y. J., Halldén G. (2018). Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus AdΔΔ through bcl-2-dependent attenuation of autophagy. Oncogenesis 7 (1), 6. doi: 10.1038/s41389-017-0020-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41389-017-0020-8</ArticleId><ArticleId IdType="pmc">PMC5833340</ArticleId><ArticleId IdType="pubmed">29362360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed A., Tait S. W. G. (2020). Targeting immunogenic cell death in cancer. Mol. Oncol. 14 (12), 2994–3006. doi: 10.1002/1878-0261.12851</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1878-0261.12851</ArticleId><ArticleId IdType="pmc">PMC7718954</ArticleId><ArticleId IdType="pubmed">33179413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang L., Li J., Dong H., Wang C., Huang J., Li M., et al. . (2022). Chimeric oncolytic adenovirus armed chemokine rantes for treatment of breast cancer. Bioeng. (Basel) 9 (8), 342. doi: 10.3390/bioengineering9080342</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering9080342</ArticleId><ArticleId IdType="pmc">PMC9332706</ArticleId><ArticleId IdType="pubmed">35892755</ArticleId></ArticleIdList></Reference><Reference><Citation>Angelova A. L., Grekova S. P., Heller A., Kuhlmann O., Soyka E., Giese T., et al. . (2014). Complementary induction of immunogenic cell death by oncolytic parvovirus h-1PV and gemcitabine in pancreatic cancer. J. Virol. 88 (10), 5263–5276. doi: 10.1128/jvi.03688-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.03688-13</ArticleId><ArticleId IdType="pmc">PMC4019131</ArticleId><ArticleId IdType="pubmed">24574398</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki H., Tazawa H., Kanaya N., Kajiwara Y., Yamada M., Hashimoto M., et al. . (2022). Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. Mol. Ther. Oncol. 27, 3–13. doi: 10.1016/j.omto.2022.09.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2022.09.003</ArticleId><ArticleId IdType="pmc">PMC9513735</ArticleId><ArticleId IdType="pubmed">36212775</ArticleId></ArticleIdList></Reference><Reference><Citation>Askari F. S., Mohebbi A., Moradi A., Javid N. (2021). The role of vesicular stomatitis virus matrix protein in autophagy in the breast cancer. Asian Pac J. Cancer Prev. 22 (1), 249–255. doi: 10.31557/apjcp.2021.22.1.249</Citation><ArticleIdList><ArticleId IdType="doi">10.31557/apjcp.2021.22.1.249</ArticleId><ArticleId IdType="pmc">PMC8184201</ArticleId><ArticleId IdType="pubmed">33507706</ArticleId></ArticleIdList></Reference><Reference><Citation>Aspirin A. P., de Los Reyes V. A., Kim Y. (2021). Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment. J. R Soc. Interface 18 (174), 20200669. doi: 10.1098/rsif.2020.0669</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2020.0669</ArticleId><ArticleId IdType="pmc">PMC7879760</ArticleId><ArticleId IdType="pubmed">33402021</ArticleId></ArticleIdList></Reference><Reference><Citation>Au G. G., Lindberg A. M., Barry R. D., Shafren D. R. (2005). Oncolysis of vascular malignant human melanoma tumors by coxsackievirus A21. Int. J. Oncol. 26, 1471–1476. doi: 10.3892/ijo.26.6.1471</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.26.6.1471</ArticleId><ArticleId IdType="pubmed">15870858</ArticleId></ArticleIdList></Reference><Reference><Citation>Benavente J., Martínez-Costas J. (2007). Avian reovirus: structure and biology. Virus Res. 123 (2), 105–119. doi: 10.1016/j.virusres.2006.09.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.09.005</ArticleId><ArticleId IdType="pubmed">17018239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bommareddy P. K., Zloza A., Rabkin S. D., Kaufman H. L. (2019). Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology 8 (7), 1591875. doi: 10.1080/2162402x.2019.1591875</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402x.2019.1591875</ArticleId><ArticleId IdType="pmc">PMC6527276</ArticleId><ArticleId IdType="pubmed">31143509</ArticleId></ArticleIdList></Reference><Reference><Citation>Botta G., Passaro C., Libertini S., Abagnale A., Barbato S., Maione A. S., et al. . (2012). Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo . Hum. Gene Ther. 23 (6), 623–634. doi: 10.1089/hum.2011.120</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2011.120</ArticleId><ArticleId IdType="pubmed">22475378</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante S., Kaufmann J. K., Veckman V., Liikanen I., Nettelbeck D. M., Hemminki O., et al. . (2015). Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. Int. J. Cancer 137, 1775–1783. doi: 10.1002/ijc.29536</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29536</ArticleId><ArticleId IdType="pubmed">25821063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante S., Koski A., Kipar A., Diaconu I., Liikanen I., Hemminki O., et al. . (2014). Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int. J. Cancer 135, 720–730. doi: 10.1002/ijc.28696</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.28696</ArticleId><ArticleId IdType="pubmed">24374597</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J. J., Short S. P., Stencel-Baerenwald J., Urbanek K., Pruijssers A. J., McAllister N., et al. . (2018). Reovirus-induced apoptosis in the intestine limits establishment of enteric infection. J. Virol. 92 (10), e02062–e02017. doi: 10.1128/jvi.02062-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02062-17</ArticleId><ArticleId IdType="pmc">PMC5923068</ArticleId><ArticleId IdType="pubmed">29514905</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu X. F., Wang M. B., Zhang Z. J., Zhao Y. H., Li M., Yan Y. L. (2015). Autophagy is involved in recombinant Newcastle disease virus (rL-RVG)-induced cell death of stomach adenocarcinoma cells in vitro . Int. J. Oncol. 47 (2), 679–689. doi: 10.3892/ijo.2015.3039</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.2015.3039</ArticleId><ArticleId IdType="pubmed">26058483</ArticleId></ArticleIdList></Reference><Reference><Citation>Buijs P. R., van Amerongen G., van Nieuwkoop S., Bestebroer T. M., van Run P. R., Kuiken T., et al. . (2014). Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy. Cancer Gene Ther. 21, 463–471. doi: 10.1038/cgt.2014.51</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2014.51</ArticleId><ArticleId IdType="pubmed">25257305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai R., Meng G., Li Y., Wang W., Diao Y., Zhao S., et al. . (2019). The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice. Exp. Biol. Med. (Maywood) 244 (12), 983–991. doi: 10.1177/1535370219861928</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370219861928</ArticleId><ArticleId IdType="pmc">PMC6879773</ArticleId><ArticleId IdType="pubmed">31299861</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D., Huang L., Zhou H., Zhang Y. (2021. a). Combining IL-10 and oncolytic adenovirus demonstrates enhanced antitumor efficacy through CD8(+) T cells. Front. Immunol. 12. doi: 10.3389/fimmu.2021.615089</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.615089</ArticleId><ArticleId IdType="pmc">PMC7952747</ArticleId><ArticleId IdType="pubmed">33717103</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Li Y. Q., Yin X. Z., Li S. Z., Zhu Y. L., Fan Y. Y., et al. . (2019). Recombinant adenoviruses expressing apoptin suppress the growth of MCF−7 breast cancer cells and affect cell autophagy. Oncol. Rep. 41 (5), 2818–2832. doi: 10.3892/or.2019.7077</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2019.7077</ArticleId><ArticleId IdType="pmc">PMC6448129</ArticleId><ArticleId IdType="pubmed">30896879</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T., Ding X., Liao Q., Gao N., Chen Y., Zhao C., et al. . (2021. b). IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. J. Immunother. Cancer 9 (1), e001647. doi: 10.1136/jitc-2020-001647</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001647</ArticleId><ArticleId IdType="pmc">PMC7843316</ArticleId><ArticleId IdType="pubmed">33504576</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng P. H., Lian S., Zhao R., Rao X. M., McMasters K. M., Zhou H. S. (2013). Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells. Virol. J. 10, 293. doi: 10.1186/1743-422x-10-293</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422x-10-293</ArticleId><ArticleId IdType="pmc">PMC3850263</ArticleId><ArticleId IdType="pubmed">24059864</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi P. I., Huang W. R., Chiu H. C., Li J. Y., Nielsen B. L., Liu H. J. (2018). Avian reovirus σA-modulated suppression of lactate dehydrogenase and upregulation of glutaminolysis and the mTOC1/eIF4E/HIF-1α pathway to enhance glycolysis and the TCA cycle for virus replication. Cell Microbiol. 20 (12), e12946. doi: 10.1111/cmi.12946</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.12946</ArticleId><ArticleId IdType="pubmed">30156372</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi P. I., Huang W. R., Lai I. H., Cheng C. Y., Liu H. J. (2013). The p17 nonstructural protein of avian reovirus triggers autophagy enhancing virus replication via activation of phosphatase and tensin deleted on chromosome 10 (PTEN) and AMP-activated protein kinase (AMPK), as well as dsRNA-dependent protein kinase (PKR)/eIF2α signaling pathways. J. Biol. Chem. 288 (5), 3571–3584. doi: 10.1074/jbc.M112.390245</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.390245</ArticleId><ArticleId IdType="pmc">PMC3561576</ArticleId><ArticleId IdType="pubmed">23233667</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu H. C., Huang W. R., Liao T. L., Chi P. I., Nielsen B. L., Liu J. H., et al. . (2018). Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin h interaction. J. Biol. Chem. 293 (32), 12542–12562. doi: 10.1074/jbc.RA118.002341</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.002341</ArticleId><ArticleId IdType="pmc">PMC6093226</ArticleId><ArticleId IdType="pubmed">29907572</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu H. C., Huang W. R., Liao T. L., Wu H. Y., Munir M., Shih W. L., et al. . (2016). Suppression of vimentin phosphorylation by the avian reovirus p17 through inhibition of CDK1 and Plk1 impacting the G2/M phase of the cell cycle. PloS One 11 (9), e0162356. doi: 10.1371/journal.pone.0162356</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0162356</ArticleId><ArticleId IdType="pmc">PMC5014334</ArticleId><ArticleId IdType="pubmed">27603133</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu H. C., Huang W. R., Wang Y. Y., Li J. Y., Liao T. L., Nielsen B. L., et al. . (2019). Heterogeneous nuclear ribonucleoprotein A1 and lamin A/C modulate nucleocytoplasmic shuttling of avian reovirus p17. J. Virol. 93 (20), e00851–e00819. doi: 10.1128/jvi.00851-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00851-19</ArticleId><ArticleId IdType="pmc">PMC6798114</ArticleId><ArticleId IdType="pubmed">31375578</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie J. D., Appel N., Canter H., Achi J. G., Elliott N. M., de Matos A. L., et al. . (2021). Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma. Mol. Ther. Oncol. 22, 539–554. doi: 10.1016/j.omto.2021.07.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2021.07.014</ArticleId><ArticleId IdType="pmc">PMC8433070</ArticleId><ArticleId IdType="pubmed">34553039</ArticleId></ArticleIdList></Reference><Reference><Citation>Christie J. D., Appel N., Zhang L., Lowe K., Kilbourne J., Daggett-Vondras J., et al. . (2022). Systemic delivery of mLIGHT-armed myxoma virus is therapeutic for later-stage syngeneic murine lung metastatic osteosarcoma. Cancers (Basel) 14 (2), 337. doi: 10.3390/cancers14020337</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14020337</ArticleId><ArticleId IdType="pmc">PMC8773855</ArticleId><ArticleId IdType="pubmed">35053501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chulu J. L., Lee L. H., Lee Y. C., Liao S. H., Lin F. L., Shih W. L., et al. . (2007). Apoptosis induction by avian reovirus through p53 and mitochondria-mediated pathway. Biochem. Biophys. Res. Commun. 356 (3), 529–535. doi: 10.1016/j.bbrc.2007.02.164</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.02.164</ArticleId><ArticleId IdType="pubmed">17379188</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado-Castano S., Sanchez-Aparicio M. T., Garcia-Sastre A., Villar E. (2015). The therapeutic effect of death: Newcastle disease virus and its antitumor potential. Virus Res. 209, 56–66. doi: 10.1016/j.virusres.2015.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2015.07.001</ArticleId><ArticleId IdType="pmc">PMC4630136</ArticleId><ArticleId IdType="pubmed">26221764</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Somma S., Iannuzzi C. A., Passaro C., Forte I. M., Iannone R., Gigantino V., et al. . (2019). The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces xenograft growth. Front. Oncol. 9. doi: 10.3389/fonc.2019.00564</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00564</ArticleId><ArticleId IdType="pmc">PMC6639422</ArticleId><ArticleId IdType="pubmed">31355131</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias J. D., Hemminki O., Diaconu I., Hirvinen M., Bonetti A., Guse K., et al. . (2012). Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 19 (10), 988–998. doi: 10.1038/gt.2011.176</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2011.176</ArticleId><ArticleId IdType="pubmed">22071969</ArticleId></ArticleIdList></Reference><Reference><Citation>Draganov D. D., Santidrian A. F., Minev I., Nguyen D., Kilinc M. O., Petrov I., et al. . (2019). Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers. J. Transl. Med. 17 (1), 100. doi: 10.1186/s12967-019-1829-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-019-1829-z</ArticleId><ArticleId IdType="pmc">PMC6437877</ArticleId><ArticleId IdType="pubmed">30917829</ArticleId></ArticleIdList></Reference><Reference><Citation>Evgin L., Huff A. L., Wongthida P., Thompson J., Kottke T., Tonne J., et al. . (2020). Oncolytic virus-derived type I interferon restricts CAR T cell therapy. Nat. Commun. 11 (1), 3187. doi: 10.1038/s41467-020-17011-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17011-z</ArticleId><ArticleId IdType="pmc">PMC7314766</ArticleId><ArticleId IdType="pubmed">32581235</ArticleId></ArticleIdList></Reference><Reference><Citation>Evgin L., Kottke T., Tonne J., Thompson J., Huff A. L., van Vloten J., et al. . (2022). Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci. Transl. Med. 14 (640), eabn2231. doi: 10.1126/scitranslmed.abn2231</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn2231</ArticleId><ArticleId IdType="pmc">PMC9297825</ArticleId><ArticleId IdType="pubmed">35417192</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng M., Zhao Z., Yang M., Ji J., Zhu D. (2021). T-Cell-based immunotherapy in colorectal cancer. Cancer Lett 498, 201–209. doi: 10.1016/j.canlet.2020.10.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2020.10.040</ArticleId><ArticleId IdType="pubmed">33129958</ArticleId></ArticleIdList></Reference><Reference><Citation>Forte I. M., Indovina P., Montagnaro S., Costa A., Iannuzzi C. A., Capone F., et al. . (2021). The oncolytic caprine herpesvirus 1 (CpHV-1) induces apoptosis and synergizes with cisplatin in mesothelioma cell lines: A new potential virotherapy approach. Viruses 13 (12), 2458. doi: 10.3390/v13122458</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13122458</ArticleId><ArticleId IdType="pmc">PMC8703924</ArticleId><ArticleId IdType="pubmed">34960727</ArticleId></ArticleIdList></Reference><Reference><Citation>Frampton J. E. (2022). Teserpaturev/G47Δ: First approval. BioDrugs 36 (5), 667–672. doi: 10.1007/s40259-022-00553-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40259-022-00553-7</ArticleId><ArticleId IdType="pubmed">36098872</ArticleId></ArticleIdList></Reference><Reference><Citation>Frumence E., Roche M., Krejbich-Trotot P., El-Kalamouni C., Nativel B., Rondeau P., et al. . (2016). The south pacific epidemic strain of zika virus replicates efficiently in human epithelial A549 cells leading to IFN-β production and apoptosis induction. Virology 493, 217–226. doi: 10.1016/j.virol.2016.03.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2016.03.006</ArticleId><ArticleId IdType="pubmed">27060565</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu X., Rivera A., Tao L., Zhang X. (2015). An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites. Oncotarget 6 (2), 902–914. doi: 10.18632/oncotarget.2817</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.2817</ArticleId><ArticleId IdType="pmc">PMC4359264</ArticleId><ArticleId IdType="pubmed">25460506</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara H., Ino Y., Todo T. (2016). Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 107 (10), 1373–1379. doi: 10.1111/cas.13027</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13027</ArticleId><ArticleId IdType="pmc">PMC5084676</ArticleId><ArticleId IdType="pubmed">27486853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaddy D. F., Lyles D. S. (2007). Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, fas, and daxx. J. Virol. 81 (6), 2792–2804. doi: 10.1128/jvi.01760-06</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01760-06</ArticleId><ArticleId IdType="pmc">PMC1865982</ArticleId><ArticleId IdType="pubmed">17192316</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganar K., Das M., Sinha S., Kumar S. (2014). Newcastle Disease virus: current status and our understanding. Virus Res. 184, 71–81. doi: 10.1016/j.virusres.2014.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.02.016</ArticleId><ArticleId IdType="pmc">PMC7127793</ArticleId><ArticleId IdType="pubmed">24589707</ArticleId></ArticleIdList></Reference><Reference><Citation>Garant K. A., Shmulevitz M., Pan L., Daigle R. M., Ahn D. G., Gujar S. A., et al. . (2016). Oncolytic reovirus induces intracellular redistribution of ras to promote apoptosis and progeny virus release. Oncogene 35 (6), 771–782. doi: 10.1038/onc.2015.136</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2015.136</ArticleId><ArticleId IdType="pubmed">25961930</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebremeskel S., Nelson A., Walker B., Oliphant T., Lobert L., Mahoney D., et al. . (2021). Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. J. Immunother. Cancer 9 (3), e002096. doi: 10.1136/jitc-2020-002096</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-002096</ArticleId><ArticleId IdType="pmc">PMC7970295</ArticleId><ArticleId IdType="pubmed">33722907</ArticleId></ArticleIdList></Reference><Reference><Citation>Glorioso J. C., Cohen J. B., Goins W. F., Hall B., Jackson J. W., Kohanbash G., et al. . (2021). Oncolytic HSV vectors and anti-tumor immunity. Curr. Issues Mol. Biol. 41, 381–468. doi: 10.21775/cimb.041.381</Citation><ArticleIdList><ArticleId IdType="doi">10.21775/cimb.041.381</ArticleId><ArticleId IdType="pubmed">32938804</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Morales A., Zabaleta A., García-Moure M., Alonso M. M., Fernández-Irigoyen J., Santamaría E. (2019). Oncolytic adenovirus delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy. J. Proteomics 194, 168–178. doi: 10.1016/j.jprot.2018.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jprot.2018.11.020</ArticleId><ArticleId IdType="pubmed">30503830</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray Z., Tabarraei A., Moradi A., Kalani M. R. (2019). M51R and delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells. Mol. Biol. Rep. 46 (3), 3371–3379. doi: 10.1007/s11033-019-04799-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-019-04799-3</ArticleId><ArticleId IdType="pubmed">31006094</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedan S., Alemany R. (2018). CAR-T cells and oncolytic viruses: Joining forces to overcome the solid tumor challenge. Front. Immunol. 9. doi: 10.3389/fimmu.2018.02460</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02460</ArticleId><ArticleId IdType="pmc">PMC6207052</ArticleId><ArticleId IdType="pubmed">30405639</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z. S., Liu Z., Bartlett D. L. (2014). Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Front. Oncol. 4. doi: 10.3389/fonc.2014.00074</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2014.00074</ArticleId><ArticleId IdType="pmc">PMC3989763</ArticleId><ArticleId IdType="pubmed">24782985</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z. S., Liu Z., Kowalsky S., Feist M., Kalinski P., Lu B., et al. . (2017). Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. Front. Immunol. 8. doi: 10.3389/fimmu.2017.00555</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00555</ArticleId><ArticleId IdType="pmc">PMC5430078</ArticleId><ArticleId IdType="pubmed">28555136</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z. S., Lu B., Guo Z., Giehl E., Feist M., Dai E., et al. . (2019). Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J. Immunother. Cancer 7 (1), 6. doi: 10.1186/s40425-018-0495-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40425-018-0495-7</ArticleId><ArticleId IdType="pmc">PMC6325819</ArticleId><ArticleId IdType="pubmed">30626434</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghighi-Najafabadi N., Roohvand F., Shams Nosrati M. S., Teimoori-Toolabi L., Azadmanesh K. (2021). Oncolytic herpes simplex virus type-1 expressing IL-12 efficiently replicates and kills human colorectal cancer cells. Microb. Pathog. 160, 105164. doi: 10.1016/j.micpath.2021.105164</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.105164</ArticleId><ArticleId IdType="pubmed">34478858</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Z., Li Q., Sun S., Zhao W., Shi L. (2019). Inactivated Sendai virus strain tianjin induces apoptosis and autophagy through reactive oxygen species production in osteosarcoma MG-63 cells. J. Cell Physiol. 234 (4), 4179–4190. doi: 10.1002/jcp.27176</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27176</ArticleId><ArticleId IdType="pubmed">30146726</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington K. J., Puzanov I., Hecht J. R., Hodi F. S., Szabo Z., Murugappan S., et al. . (2015). Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev. Anticancer Ther. 15 (12), 1389–1403. doi: 10.1586/14737140.2015.1115725</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737140.2015.1115725</ArticleId><ArticleId IdType="pubmed">26558498</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidbuechel J. P. W., Engeland C. E. (2021). Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J. Hematol. Oncol. 14 (1), 63. doi: 10.1186/s13045-021-01075-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-021-01075-5</ArticleId><ArticleId IdType="pmc">PMC8052795</ArticleId><ArticleId IdType="pubmed">33863363</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C. Y., Chen Y. H., Huang W. R., Huang J. W., Chen I. C., Chang Y. K., et al. . (2022). Oncolytic avian reovirus σA-modulated fatty acid metabolism through the PSMB6/Akt/SREBP1/acetyl-CoA carboxylase pathway to increase energy production for virus replication. Vet. Microbiol. 273, 109545. doi: 10.1016/j.vetmic.2022.109545</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2022.109545</ArticleId><ArticleId IdType="pubmed">35998542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C. Y., Huang J. W., Huang W. R., Chen I. C., Chen M. S., Liao T. L., et al. . (2023). Oncolytic avian reovirus σA-modulated upregulation of the HIF-1α/C-myc/glut1 pathway to produce more energy in different cancer cell lines benefiting virus replication. Viruses. 15 (2), 523. doi: 10.3390/v15020523</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020523</ArticleId><ArticleId IdType="pmc">PMC9961784</ArticleId><ArticleId IdType="pubmed">36851737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J., Wang H., Gu J., Liu X., Zhou X. (2018). Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. Acta Biochim. Biophys. Sin. (Shanghai) 50 (10), 1018–1027. doi: 10.1093/abbs/gmy096</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abbs/gmy096</ArticleId><ArticleId IdType="pubmed">30137199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J. C., Coffin R. S., Davis C. J., Graham N. J., Groves N., Guest P. J., et al. . (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin. Cancer Res. 12 (22), 6737–6747. doi: 10.1158/1078-0432.Ccr-06-0759</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-06-0759</ArticleId><ArticleId IdType="pubmed">17121894</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu L., Sun S., Wang T., Li Y., Jiang K., Lin G., et al. . (2015). Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. Am. J. Cancer Res. 5 (12), 3612–3623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731635</ArticleId><ArticleId IdType="pubmed">26885450</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Zheng M., Zhang Z., Tang X., Chen Y., Peng A., et al. . (2021). Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol. Immunother. 70 (9), 2453–2465. doi: 10.1007/s00262-021-02856-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00262-021-02856-0</ArticleId><ArticleId IdType="pmc">PMC10991970</ArticleId><ArticleId IdType="pubmed">33543339</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W. R., Chi P. I., Chiu H. C., Hsu J. L., Nielsen B. L., Liao T. L., et al. . (2017). Avian reovirus p17 and σA act cooperatively to downregulate akt by suppressing mTORC2 and CDK2/cyclin A2 and upregulating proteasome PSMB6. Sci. Rep. 7 (1), 5226. doi: 10.1038/s41598-017-05510-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-05510-x</ArticleId><ArticleId IdType="pmc">PMC5507987</ArticleId><ArticleId IdType="pubmed">28701787</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W. R., Chiu H. C., Liao T. L., Chuang K. P., Shih W. L., Liu H. J. (2015). Avian reovirus protein p17 functions as a nucleoporin tpr suppressor leading to activation of p53, p21 and PTEN and inactivation of PI3K/AKT/mTOR and ERK signaling pathways. PloS One 10 (8), e0133699. doi: 10.1371/journal.pone.0133699</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133699</ArticleId><ArticleId IdType="pmc">PMC4526660</ArticleId><ArticleId IdType="pubmed">26244501</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W. R., Li J. Y., Liao T. L., Yeh C. M., Wang C. Y., Wen H. W., et al. . (2022. a). Molecular chaperone TRiC governs avian reovirus replication by protecting outer-capsid protein σC and inner core protein σA and non-structural protein σNS from ubiquitin- proteasome degradation. Vet. Microbiol. 264, 109277. doi: 10.1016/j.vetmic.2021.109277</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vetmic.2021.109277</ArticleId><ArticleId IdType="pubmed">34826648</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang W. R., Li J. Y., Wu Y. Y., Liao T. L., Nielsen B. L., Liu H. J. (2022. b). p17-modulated Hsp90/Cdc37 complex governs oncolytic avian reovirus replication by chaperoning p17, which promotes viral protein synthesis and accumulation of viral proteins σC and σA in viral factories. J. Virol. 96 (6), e0007422. doi: 10.1128/jvi.00074-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00074-22</ArticleId><ArticleId IdType="pmc">PMC8941905</ArticleId><ArticleId IdType="pubmed">35107368</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue H., Tani K. (2014). Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 21 (1), 39–49. doi: 10.1038/cdd.2013.84</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2013.84</ArticleId><ArticleId IdType="pmc">PMC3857623</ArticleId><ArticleId IdType="pubmed">23832118</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue T., Byrne T., Inoue M., Tait M. E., Wall P., Wang A., et al. . (2021). Oncolytic vaccinia virus gene modification and cytokine expression effects on tumor infection, immune response, and killing. Mol. Cancer Ther. 20 (8), 1481–1494. doi: 10.1158/1535-7163.Mct-20-0863</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.Mct-20-0863</ArticleId><ArticleId IdType="pmc">PMC8338778</ArticleId><ArticleId IdType="pubmed">34045231</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang K., Li Y., Zhu Q., Xu J., Wang Y., Deng W., et al. . (2014). Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells. BMC Cancer 14, 551. doi: 10.1186/1471-2407-14-551</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2407-14-551</ArticleId><ArticleId IdType="pmc">PMC4141091</ArticleId><ArticleId IdType="pubmed">25078870</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiffry J., Thavornwatanayong T., Rao D., Fogel E. J., Saytoo D., Nahata R., et al. . (2021). Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer. Clin. Cancer Res. 27 (3), 865–876. doi: 10.1158/1078-0432.Ccr-20-2385</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-20-2385</ArticleId><ArticleId IdType="pmc">PMC8130598</ArticleId><ArticleId IdType="pubmed">33168658</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J., Wang R., Yang J., Hu H., Wang D., Cai L., et al. . (2022). Bispecific antibody expressed by an oncolytic herpes simplex virus type 2 can transform heterologous T cells into uniform tumor killer cells. Hum. Gene Ther. 33 (11-12), 649–663. doi: 10.1089/hum.2021.277</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/hum.2021.277</ArticleId><ArticleId IdType="pmc">PMC9242723</ArticleId><ArticleId IdType="pubmed">35272497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin K. T., Tao X. H., Fan Y. B., Wang S. B. (2021). Crosstalk between oncolytic viruses and autophagy in cancer therapy. BioMed. Pharmacother. 134, 110932. doi: 10.1016/j.biopha.2020.110932</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110932</ArticleId><ArticleId IdType="pubmed">33370632</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon Y. H., Jung Y. T. (2022). Production of a replicating retroviral vector expressing reovirus fast protein for cancer gene therapy. J. Virol. Methods 299, 114332. doi: 10.1016/j.jviromet.2021.114332</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114332</ArticleId><ArticleId IdType="pubmed">34655690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalus P., De Munck J., Vanbellingen S., Carreer L., Laeremans T., Broos K., et al. . (2022). Oncolytic herpes simplex virus type 1 induces immunogenic cell death resulting in maturation of BDCA-1(+) myeloid dendritic cells. Int. J. Mol. Sci. 23 (9), 4865. doi: 10.3390/ijms23094865</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23094865</ArticleId><ArticleId IdType="pmc">PMC9103433</ArticleId><ArticleId IdType="pubmed">35563257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyanasundram J., Hamid A., Yusoff K., Chia S. L. (2018). Newcastle Disease virus strain AF2240 as an oncolytic virus: A review. Acta Trop. 183, 126–133. doi: 10.1016/j.actatropica.2018.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.actatropica.2018.04.007</ArticleId><ArticleId IdType="pubmed">29626432</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamynina M., Tskhovrebova S., Fares J., Timashev P., Laevskaya A., Ulasov I. (2021). Oncolytic virus-induced autophagy in glioblastoma. Cancers (Basel) 13 (14), 3482. doi: 10.3390/cancers13143482</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13143482</ArticleId><ArticleId IdType="pmc">PMC8304501</ArticleId><ArticleId IdType="pubmed">34298694</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanaya N., Kuroda S., Kakiuchi Y., Kumon K., Tsumura T., Hashimoto M., et al. . (2020). Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody. Mol. Ther. 28 (3), 794–804. doi: 10.1016/j.ymthe.2020.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.003</ArticleId><ArticleId IdType="pmc">PMC7054725</ArticleId><ArticleId IdType="pubmed">31991110</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly E., Russell S. J. (2007). History of oncolytic viruses: genesis to genetic engineering. Mol. Ther. 15, 651–659. doi: 10.1038/sj.mt.6300108</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mt.6300108</ArticleId><ArticleId IdType="pubmed">17299401</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarz M., Solaymani-Mohammadi F., Miri S. M., Ghaemi A. (2019). Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy. J. BioMed. Sci. 26 (1), 48. doi: 10.1186/s12929-019-0542-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0542-9</ArticleId><ArticleId IdType="pmc">PMC6585078</ArticleId><ArticleId IdType="pubmed">31217023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D. S., Dastidar H., Zhang C., Zemp F. J., Lau K., Ernst M., et al. . (2017). Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Nat. Commun. 8 (1), 344. doi: 10.1038/s41467-017-00324-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00324-x</ArticleId><ArticleId IdType="pmc">PMC5570934</ArticleId><ArticleId IdType="pubmed">28839138</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K. J., Moon D., Kong S. J., Lee Y. S., Yoo Y., Kim S., et al. . (2021). Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. Gene Ther. 28 (3-4), 186–198. doi: 10.1038/s41434-020-00205-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-020-00205-x</ArticleId><ArticleId IdType="pubmed">33149278</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S. R., Piya S., Lu Z., Xia Y., Alonso M. M., White E. J., et al. . (2015). C-jun n-terminal kinases are required for oncolytic adenovirus-mediated autophagy. Oncogene 34 (41), 5295–5301. doi: 10.1038/onc.2014.452</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2014.452</ArticleId><ArticleId IdType="pmc">PMC4515398</ArticleId><ArticleId IdType="pubmed">25619840</ArticleId></ArticleIdList></Reference><Reference><Citation>Klose C., Berchtold S., Schmidt M., Beil J., Smirnow I., Venturelli S., et al. . (2019). Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy. BMC Cancer 19 (1), 1172. doi: 10.1186/s12885-019-6387-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-019-6387-5</ArticleId><ArticleId IdType="pmc">PMC6889644</ArticleId><ArticleId IdType="pubmed">31795974</ArticleId></ArticleIdList></Reference><Reference><Citation>Koks C. A., Garg A. D., Ehrhardt M., Riva M., Vandenberk L., Boon L., et al. . (2015). Newcastle Disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int. J. Cancer 136, E313–E325. doi: 10.1002/ijc.29202</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.29202</ArticleId><ArticleId IdType="pubmed">25208916</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontermann R. E., Ungerechts G., Nettelbeck D. M. (2021). Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. MAbs 13 (1), 1982447. doi: 10.1080/19420862.2021.1982447</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2021.1982447</ArticleId><ArticleId IdType="pmc">PMC8583164</ArticleId><ArticleId IdType="pubmed">34747345</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J., Kis Z., Josupeit R., Schlund F., Stroh-Dege A., Frank-Stöhr M., et al. . (2018). Preclinical testing of an oncolytic parvovirus in ewing sarcoma: Protoparvovirus h-1 induces apoptosis and lytic infection in vitro but fails to improve survival in vivo. Viruses 10 (6), 302. doi: 10.3390/v10060302</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v10060302</ArticleId><ArticleId IdType="pmc">PMC6024310</ArticleId><ArticleId IdType="pubmed">29865280</ArticleId></ArticleIdList></Reference><Reference><Citation>Lal G., Rajala M. S. (2018). Combination of oncolytic measles virus armed with BNiP3, a pro-apoptotic gene and paclitaxel induces breast cancer cell death. Front. Oncol. 8. doi: 10.3389/fonc.2018.00676</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00676</ArticleId><ArticleId IdType="pmc">PMC6340943</ArticleId><ArticleId IdType="pubmed">30697531</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei W., Wang S., Xu N., Chen Y., Wu G., Zhang A., et al. . (2020). Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with beclin-1, an autophagic gene in leukemia and myeloma. BioMed. Pharmacother. 125, 110030. doi: 10.1016/j.biopha.2020.110030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110030</ArticleId><ArticleId IdType="pubmed">32187960</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Meng Q., Zhou X., Zhao H., Wang K., Niu H., et al. . (2022. a). Gospel of malignant glioma: Oncolytic virus therapy. Gene 818, 146217. doi: 10.1016/j.gene.2022.146217</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2022.146217</ArticleId><ArticleId IdType="pubmed">35093451</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J. Y., Huang W. R., Liao T. L., Nielsen B. L., Liu H. J. (2022. b). Oncolytic avian reovirus p17-modulated inhibition of mTORC1 by enhancement of endogenous mTORC1 inhibitors binding to mTORC1 to disrupt its assembly and accumulation on lysosomes. J. Virol. 96 (17), e0083622. doi: 10.1128/jvi.00836-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00836-22</ArticleId><ArticleId IdType="pmc">PMC9472607</ArticleId><ArticleId IdType="pubmed">35946936</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Hu C., Xing F., Gao M., Liang J., Xiao X., et al. . (2018). Deficiency of the IRE1α-autophagy axis enhances the antitumor effects of the oncolytic virus M1. J. Virol. 92 (6), e01331–e01317. doi: 10.1128/jvi.01331-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01331-17</ArticleId><ArticleId IdType="pmc">PMC5827398</ArticleId><ArticleId IdType="pubmed">29263275</ArticleId></ArticleIdList></Reference><Reference><Citation>Liikanen I., Ahtiainen L., Hirvinen M. L., Bramante S., Cerullo V., Nokisalmi P., et al. . (2013). Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol. Ther. 21 (6), 1212–1223. doi: 10.1038/mt.2013.51</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.51</ArticleId><ArticleId IdType="pmc">PMC3681222</ArticleId><ArticleId IdType="pubmed">23546299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P. Y., Chang C. D., Chen Y. C., Shih W. L. (2015). RhoA/ROCK1 regulates avian reovirus S1133-induced switch from autophagy to apoptosis. BMC Vet. Res. 11, 103. doi: 10.1186/s12917-015-0417-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12917-015-0417-6</ArticleId><ArticleId IdType="pmc">PMC4430033</ArticleId><ArticleId IdType="pubmed">25944062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P. Y., Lee J. W., Liao M. H., Hsu H. Y., Chiu S. J., Liu H. J., et al. . (2009). Modulation of p53 by mitogen-activated protein kinase pathways and protein kinase c delta during avian reovirus S1133-induced apoptosis. Virology 385 (2), 323–334. doi: 10.1016/j.virol.2008.12.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.12.028</ArticleId><ArticleId IdType="pubmed">19168198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P. Y., Liu H. J., Chang C. D., Chang C. I., Hsu J. L., Liao M. H., et al. . (2011). Avian reovirus S1133-induced DNA damage signaling and subsequent apoptosis in cultured cells and in chickens. Arch. Virol. 156 (11), 1917–1929. doi: 10.1007/s00705-011-1063-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-011-1063-3</ArticleId><ArticleId IdType="pubmed">21779911</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P. Y., Liu H. J., Liao M. H., Chang C. D., Chang C. I., Cheng H. L., et al. . (2010). Activation of PI 3-kinase/Akt/NF-kappaB and Stat3 signaling by avian reovirus S1133 in the early stages of infection results in an inflammatory response and delayed apoptosis. Virology 400 (1), 104–114. doi: 10.1016/j.virol.2010.01.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.01.024</ArticleId><ArticleId IdType="pubmed">20170934</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H. J., Lin P. Y., Wang L. R., Hsu H. Y., Liao M. H., Shih W. L. (2008). Activation of small GTPases RhoA and Rac1 is required for avian reovirus p10-induced syncytium formation. Mol. Cells 26 (4), 396–403.</Citation><ArticleIdList><ArticleId IdType="pubmed">18612239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorence R. M., Rood P. A., Kelley K. W. (1988). Newcastle Disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J. Natl. Cancer Inst 80 (16), 1305–1312. doi: 10.1093/jnci/80.16.1305</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/80.16.1305</ArticleId><ArticleId IdType="pubmed">2459402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu M., Wei F., Ma S., Xu Z., Wang J., Yang C., et al. . (2021). Oncolytic virus as a novel modality for the treatment of prostate cancer. Discovery Med. 32 (167), 133–139.</Citation><ArticleIdList><ArticleId IdType="pubmed">35220999</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv C., Su Q., Liang Y., Hu J., Yuan S. (2016). Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis. Biochem. Biophys. Res. Commun. 476 (1), 21–28. doi: 10.1016/j.bbrc.2016.05.088</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2016.05.088</ArticleId><ArticleId IdType="pubmed">27208781</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Ramachandran M., Jin C., Quijano-Rubio C., Martikainen M., Yu D., et al. . (2020). Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. Cell Death Dis. 11 (1), 48. doi: 10.1038/s41419-020-2236-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-2236-3</ArticleId><ArticleId IdType="pmc">PMC6976683</ArticleId><ArticleId IdType="pubmed">31969562</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma R., Lu T., Li Z., Teng K. Y., Mansour A. G., Yu M., et al. . (2021). An oncolytic virus expressing IL15/IL15Rα combined with off-the-Shelf EGFR-CAR NK cells targets glioblastoma. Cancer Res. 81 (13), 3635–3648. doi: 10.1158/0008-5472.Can-21-0035</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-21-0035</ArticleId><ArticleId IdType="pmc">PMC8562586</ArticleId><ArticleId IdType="pubmed">34006525</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W., He H., Wang H. (2018). Oncolytic herpes simplex virus and immunotherapy. BMC Immunol. 19 (1), 40. doi: 10.1186/s12865-018-0281-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-018-0281-9</ArticleId><ArticleId IdType="pmc">PMC6299639</ArticleId><ArticleId IdType="pubmed">30563466</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud M. H., Badr G., Badr B. M., Kassem A. U., Mohamed M. S. (2015). Elevated IFN-alpha/beta levels in a streptozotocin-induced type I diabetic mouse model promote oxidative stress and mediate depletion of spleen-homing CD8+ T cells by apoptosis through impaired CCL21/CCR7 axis and IL-7/CD127 signaling. Cell Signal 27 (10), 2110–2119. doi: 10.1016/j.cellsig.2015.07.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2015.07.005</ArticleId><ArticleId IdType="pubmed">26192098</ArticleId></ArticleIdList></Reference><Reference><Citation>Malogolovkin A., Gasanov N., Egorov A., Weener M., Ivanov R., Karabelsky A. (2021). Combinatorial approaches for cancer treatment using oncolytic viruses: Projecting the perspectives through clinical trials outcomes. Viruses 13 (7), 1271. doi: 10.3390/v13071271</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071271</ArticleId><ArticleId IdType="pmc">PMC8309967</ArticleId><ArticleId IdType="pubmed">34209981</ArticleId></ArticleIdList></Reference><Reference><Citation>Manocha E., Bugatti A., Belleri M., Zani A., Marsico S., Caccuri F., et al. . (2021. a). Avian reovirus P17 suppresses angiogenesis by promoting DPP4 secretion. Cells 10 (2), 259. doi: 10.3390/cells10020259</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020259</ArticleId><ArticleId IdType="pmc">PMC7911508</ArticleId><ArticleId IdType="pubmed">33525607</ArticleId></ArticleIdList></Reference><Reference><Citation>Manocha E., Caruso A., Caccuri F. (2021. b). Viral proteins as emerging cancer therapeutics. Cancers (Basel) 13 (9), 2199. doi: 10.3390/cancers13092199</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13092199</ArticleId><ArticleId IdType="pmc">PMC8125098</ArticleId><ArticleId IdType="pubmed">34063663</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansour M., Palese P., Zamarin D. (2011). Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85 (12), 6015–6023. doi: 10.1128/jvi.01537-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01537-10</ArticleId><ArticleId IdType="pmc">PMC3126310</ArticleId><ArticleId IdType="pubmed">21471241</ArticleId></ArticleIdList></Reference><Reference><Citation>Mardi A., Shirokova A. V., Mohammed R. N., Keshavarz A., Zekiy A. O., Thangavelu L., et al. . (2022). Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int. 22 (1), 168. doi: 10.1186/s12935-022-02585-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12935-022-02585-z</ArticleId><ArticleId IdType="pmc">PMC9052538</ArticleId><ArticleId IdType="pubmed">35488303</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng C., Zhou Z., Jiang K., Yu S., Jia L., Wu Y., et al. . (2012). Newcastle Disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch. Virol. 157 (6), 1011–1018. doi: 10.1007/s00705-012-1270-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-012-1270-6</ArticleId><ArticleId IdType="pmc">PMC7087167</ArticleId><ArticleId IdType="pubmed">22398914</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng S., Xu J., Wu Y., Ding C. (2013). Targeting autophagy to enhance oncolytic virus-based cancer therapy. Expert Opin. Biol. Ther. 13 (6), 863–873. doi: 10.1517/14712598.2013.774365</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2013.774365</ArticleId><ArticleId IdType="pubmed">23488666</ArticleId></ArticleIdList></Reference><Reference><Citation>Mistarz A., Graczyk M., Winkler M., Singh P. K., Cortes E., Miliotto A., et al. . (2021). Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. Mol. Ther. Oncol. 23, 38–50. doi: 10.1016/j.omto.2021.04.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omto.2021.04.014</ArticleId><ArticleId IdType="pmc">PMC8479291</ArticleId><ArticleId IdType="pubmed">34632049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondal M., Guo J., He P., Zhou D. (2020). Recent advances of oncolytic virus in cancer therapy. Hum. Vaccin Immunother. 16 (10), 2389–2402. doi: 10.1080/21645515.2020.1723363</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1723363</ArticleId><ArticleId IdType="pmc">PMC7644205</ArticleId><ArticleId IdType="pubmed">32078405</ArticleId></ArticleIdList></Reference><Reference><Citation>Moralès O., Richard A., Martin N., Mrizak D., Sénéchal M., Miroux C., et al. . (2012). Activation of a helper and not regulatory human CD4+ T cell response by oncolytic h-1 parvovirus. PloS One 7 (2), e32197. doi: 10.1371/journal.pone.0032197</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032197</ArticleId><ArticleId IdType="pmc">PMC3281136</ArticleId><ArticleId IdType="pubmed">22359669</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno R. (2021). Mesenchymal stem cells and oncolytic viruses: joining forces against cancer. J. Immunother. Cancer 9 (2), e001684. doi: 10.1136/jitc-2020-001684</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001684</ArticleId><ArticleId IdType="pmc">PMC7871674</ArticleId><ArticleId IdType="pubmed">33558278</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno R., Fajardo C. A., Farrera-Sal M., Perisé-Barrios A. J., Morales-Molina A., Al-Zaher A. A., et al. . (2019). Enhanced antitumor efficacy of oncolytic adenovirus-loaded menstrual blood-derived mesenchymal stem cells in combination with peripheral blood mononuclear cells. Mol. Cancer Ther. 18 (1), 127–138. doi: 10.1158/1535-7163.Mct-18-0431</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1535-7163.Mct-18-0431</ArticleId><ArticleId IdType="pubmed">30322950</ArticleId></ArticleIdList></Reference><Reference><Citation>Morla S., Kumar A., Kumar S. (2019). Newcastle Disease virus mediated apoptosis and migration inhibition of human oral cancer cells: A probable role of β-catenin and matrix metalloproteinase-7. Sci. Rep. 9 (1), 10882. doi: 10.1038/s41598-019-47244-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-47244-y</ArticleId><ArticleId IdType="pmc">PMC6659693</ArticleId><ArticleId IdType="pubmed">31350432</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrish E., Brumatti G., Silke J. (2020). Future therapeutic directions for smac-mimetics. Cells 9 (2), 406. doi: 10.3390/cells9020406</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9020406</ArticleId><ArticleId IdType="pmc">PMC7072318</ArticleId><ArticleId IdType="pubmed">32053868</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozaffari Nejad A. S., Fotouhi F., Mehrbod P., Keshavarz M., Alikhani M. Y., Ghaemi A. (2020). Oncolytic effects of hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome c, autophagy and apoptotic pathways. Microb. Pathog. 147, 104438. doi: 10.1016/j.micpath.2020.104438</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104438</ArticleId><ArticleId IdType="pubmed">32777353</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair S., Mazzoccoli L., Jash A., Govero J., Bais S. S., Hu T., et al. . (2021). Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI Insight 6 (1), e144619. doi: 10.1172/jci.insight.144619</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.144619</ArticleId><ArticleId IdType="pmc">PMC7821591</ArticleId><ArticleId IdType="pubmed">33232299</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen T. T., Shin D. H., Sohoni S., Singh S. K., Rivera-Molina Y., Jiang H., et al. . (2022). Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. J. Immunother. Cancer 10 (7), e004935. doi: 10.1136/jitc-2022-004935</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2022-004935</ArticleId><ArticleId IdType="pmc">PMC9341188</ArticleId><ArticleId IdType="pubmed">35902132</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh E., Hong J., Kwon O. J., Yun C. O. (2018). A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma. Sci. Rep. 8 (1), 1420. doi: 10.1038/s41598-018-19300-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19300-6</ArticleId><ArticleId IdType="pmc">PMC5780382</ArticleId><ArticleId IdType="pubmed">29362367</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku M., Ishino R., Uchida S., Imataki O., Sugimoto N., Todo T., et al. . (2021). Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms. Br. J. Haematol 192 (2), 343–353. doi: 10.1111/bjh.17173</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17173</ArticleId><ArticleId IdType="pubmed">33216988</ArticleId></ArticleIdList></Reference><Reference><Citation>Packiriswamy N., Upreti D., Zhou Y., Khan R., Miller A., Diaz R. M., et al. . (2020). Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia 34 (12), 3310–3322. doi: 10.1038/s41375-020-0828-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-020-0828-7</ArticleId><ArticleId IdType="pmc">PMC7581629</ArticleId><ArticleId IdType="pubmed">32327728</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandha H., Harrington K., Ralph C., Melcher A., Shafren D. R. (2015). Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients. Cancer Res. 75, CT205. doi: 10.1158/1538-7445.AM2015-CT205</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1538-7445.AM2015-CT205</ArticleId></ArticleIdList></Reference><Reference><Citation>Pol J., Kroemer G., Galluzzi L. (2016). First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology 5 (1), e1115641. doi: 10.1080/2162402x.2015.1115641</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402x.2015.1115641</ArticleId><ArticleId IdType="pmc">PMC4760283</ArticleId><ArticleId IdType="pubmed">26942095</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian M., Tan H. M., Yu N., Wang T., Zhang Q. (2018). Inactivated sendai virus induces ROS-dependent apoptosis and autophagy in human prostate cancer cells. BioMed. Environ. Sci. 31 (4), 280–289. doi: 10.3967/bes2018.036</Citation><ArticleIdList><ArticleId IdType="doi">10.3967/bes2018.036</ArticleId><ArticleId IdType="pubmed">29773091</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajecki M., af Hällström T., Hakkarainen T., Nokisalmi P., Hautaniemi S., Nieminen A. I., et al. . (2009). Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. Int. J. Cancer 125 (10), 2441–2449. doi: 10.1002/ijc.24608</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.24608</ArticleId><ArticleId IdType="pubmed">19672857</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranki T., Joensuu T., Jager E., Karbach J., Wahle C., Kairemo K., et al. . (2014). Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 T-cell response, prominent infiltration of CD8 lymphocytes and Th1 type polarization. Oncoimmunology 3, e958937. doi: 10.4161/21624011.2014.958937</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/21624011.2014.958937</ArticleId><ArticleId IdType="pmc">PMC4292415</ArticleId><ArticleId IdType="pubmed">25941579</ArticleId></ArticleIdList></Reference><Reference><Citation>Ripp J., Hentzen S., Saeed A. (2022). Oncolytic viruses as an adjunct to immune checkpoint inhibition. Front. Biosci. (Landmark Ed) 27 (5), 151. doi: 10.31083/j.fbl2705151</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.fbl2705151</ArticleId><ArticleId IdType="pubmed">35638418</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivadeneira D. B., DePeaux K., Wang Y., Kulkarni A., Tabib T., Menk A. V., et al. . (2019). Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity 51 (3), 548–560.e544. doi: 10.1016/j.immuni.2019.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.07.003</ArticleId><ArticleId IdType="pmc">PMC6903394</ArticleId><ArticleId IdType="pubmed">31471106</ArticleId></ArticleIdList></Reference><Reference><Citation>Robles-Planells C., Barrera-Avalos C., Rojo L. E., Spencer E., Cortez-San Martin M., Matiacevich S., et al. . (2020). Chitosan-based delivery of avian reovirus fusogenic protein p10 gene: In vitro and in vivo studies towards a new vaccine against melanoma. BioMed. Res. Int. 2020, 4045760. doi: 10.1155/2020/4045760</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/4045760</ArticleId><ArticleId IdType="pmc">PMC7306838</ArticleId><ArticleId IdType="pubmed">32626742</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Rocha H., Gomez-Gutierrez J. G., Garcia-Garcia A., Rao X. M., Chen L., McMasters K. M., et al. . (2011). Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology 416 (1-2), 9–15. doi: 10.1016/j.virol.2011.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.04.017</ArticleId><ArticleId IdType="pmc">PMC3113480</ArticleId><ArticleId IdType="pubmed">21575980</ArticleId></ArticleIdList></Reference><Reference><Citation>Rommelfanger D. M., Compte M., Grau M. C., Diaz R. M., Ilett E., Alvarez-Vallina L., et al. . (2013). The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol. Ther. 21 (2), 348–357. doi: 10.1038/mt.2012.204</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2012.204</ArticleId><ArticleId IdType="pmc">PMC3594029</ArticleId><ArticleId IdType="pubmed">23011032</ArticleId></ArticleIdList></Reference><Reference><Citation>Roulleaux Dugage M., Nassif E. F., Italiano A., Bahleda R. (2021). Improving immunotherapy efficacy in soft-tissue sarcomas: A biomarker driven and histotype tailored review. Front. Immunol. 12. doi: 10.3389/fimmu.2021.775761</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.775761</ArticleId><ArticleId IdType="pmc">PMC8678134</ArticleId><ArticleId IdType="pubmed">34925348</ArticleId></ArticleIdList></Reference><Reference><Citation>Roulstone V., Khan K., Pandha H. S., Rudman S., Coffey M., Gill G. M., et al. . (2015). Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin. Cancer Res. 21 (6), 1305–1312. doi: 10.1158/1078-0432.Ccr-14-1770</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.Ccr-14-1770</ArticleId><ArticleId IdType="pmc">PMC4821068</ArticleId><ArticleId IdType="pubmed">25424857</ArticleId></ArticleIdList></Reference><Reference><Citation>Roulstone V., Twigger K., Zaidi S., Pencavel T., Kyula J. N., White C., et al. . (2013). Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. Gene Ther. 20 (5), 521–528. doi: 10.1038/gt.2012.68</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gt.2012.68</ArticleId><ArticleId IdType="pmc">PMC4821071</ArticleId><ArticleId IdType="pubmed">22895509</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell S. J., Barber G. N. (2018). Oncolytic viruses as antigen-agnostic cancer vaccines. Cancer Cell 33 (4), 599–605. doi: 10.1016/j.ccell.2018.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccell.2018.03.011</ArticleId><ArticleId IdType="pmc">PMC5918693</ArticleId><ArticleId IdType="pubmed">29634947</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha D., Wakimoto H., Rabkin S. D. (2016). Oncolytic herpes simplex virus interactions with the host immune system. Curr. Opin. Virol. 21, 26–34. doi: 10.1016/j.coviro.2016.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2016.07.007</ArticleId><ArticleId IdType="pmc">PMC5138121</ArticleId><ArticleId IdType="pubmed">27497296</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiller M., Parcina M., Heyder P., Foermer S., Ostrop J., Leo A., et al. . (2012). Induction of type I IFN is a physiological immune reaction to apoptotic cell-derived membrane microparticles. J. Immunol. 189 (4), 1747–1756. doi: 10.4049/jimmunol.1100631</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1100631</ArticleId><ArticleId IdType="pubmed">22786771</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirrmacher V. (2015). Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. a biologic agent with potential to break therapy resistance. Expert Opin. Biol. Ther. 5, 1757–1771. doi: 10.1517/14712598.2015.1088000</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.2015.1088000</ArticleId><ArticleId IdType="pubmed">26436571</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirrmacher V. (2016). Fifty years of clinical application of newcastle disease virus: time to celebrate! Biomedicines 4 (3), 16. doi: 10.3390/biomedicines4030016</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines4030016</ArticleId><ArticleId IdType="pmc">PMC5344264</ArticleId><ArticleId IdType="pubmed">28536382</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirrmacher V., Fournier P. (2014). Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies. Front. Oncol. 4. doi: 10.3389/fonc.2014.00224</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2014.00224</ArticleId><ArticleId IdType="pmc">PMC4160967</ArticleId><ArticleId IdType="pubmed">25309868</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao X., Wang X., Guo X., Jiang K., Ye T., Chen J., et al. . (2019). STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells. Front. Oncol. 9. doi: 10.3389/fonc.2019.00436</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.00436</ArticleId><ArticleId IdType="pmc">PMC6548873</ArticleId><ArticleId IdType="pubmed">31192135</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Zheng D. (2009). An update on gene therapy in China. Curr. Opin. Mol. Ther. 11 (5), 547–553.</Citation><ArticleIdList><ArticleId IdType="pubmed">19806503</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih W. L., Hsu H. W., Liao M. H., Lee L. H., Liu H. J. (2004). Avian reovirus sigmaC protein induces apoptosis in cultured cells. Virology 321 (1), 65–74. doi: 10.1016/j.virol.2003.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2003.12.004</ArticleId><ArticleId IdType="pubmed">15033566</ArticleId></ArticleIdList></Reference><Reference><Citation>Shmulevitz M., Salsman J., Duncan R. (2003). Palmitoylation, membrane-proximal basic residues, and transmembrane glycine residues in the reovirus p10 protein are essential for syncytium formation. J. Virol. 77 (18), 9769–9779. doi: 10.1128/jvi.77.18.9769-9779.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.77.18.9769-9779.2003</ArticleId><ArticleId IdType="pmc">PMC224572</ArticleId><ArticleId IdType="pubmed">12941885</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobhanimonfared F., Bamdad T., Sadigh Z. A., Choobin H. (2020). Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy. Microb. Pathog. 140, 103957. doi: 10.1016/j.micpath.2019.103957</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2019.103957</ArticleId><ArticleId IdType="pubmed">31891795</ArticleId></ArticleIdList></Reference><Reference><Citation>Takasu A., Masui A., Hamada M., Imai T., Iwai S., Yura Y. (2016). Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. Cancer Gene Ther. 23 (4), 107–113. doi: 10.1038/cgt.2016.8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cgt.2016.8</ArticleId><ArticleId IdType="pubmed">26987291</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayeb S., Zakay-Rones Z., Panet A. (2015). Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncol. Virother 4, 49–62. doi: 10.2147/OV.S78600</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OV.S78600</ArticleId><ArticleId IdType="pmc">PMC4918379</ArticleId><ArticleId IdType="pubmed">27512670</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazawa H., Kagawa S., Fujiwara T. (2013). Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. Acta Med. Okayama 67 (6), 333–342. doi: 10.18926/amo/52006</Citation><ArticleIdList><ArticleId IdType="doi">10.18926/amo/52006</ArticleId><ArticleId IdType="pubmed">24356717</ArticleId></ArticleIdList></Reference><Reference><Citation>Turpin J., El Safadi D., Lebeau G., Krejbich M., Chatelain C., Desprès P., et al. . (2022). Apoptosis during ZIKA virus infection: Too soon or too late? Int. J. Mol. Sci. 23 (3), 1287. doi: 10.3390/ijms23031287</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23031287</ArticleId><ArticleId IdType="pmc">PMC8835863</ArticleId><ArticleId IdType="pubmed">35163212</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchelli E., Eggermont A., Sautes-Fridman C., Galon J., Zitvogel L., Kroemer G., et al. . (2013). Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2 (6), e24612. doi: 10.4161/onci.24612</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/onci.24612</ArticleId><ArticleId IdType="pmc">PMC3716755</ArticleId><ArticleId IdType="pubmed">23894720</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vloten J. P., Workenhe S. T., Wootton S. K., Mossman K. L., Bridle B. W. (2018). Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies. J. Immunol. 200 (2), 450–458. doi: 10.4049/jimmunol.1701021</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1701021</ArticleId><ArticleId IdType="pubmed">29311387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Kang X., Chen K. S., Jehng T., Jones L., Chen J., et al. . (2020. a). An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat. Commun. 11 (1), 1395. doi: 10.1038/s41467-020-15229-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15229-5</ArticleId><ArticleId IdType="pmc">PMC7070065</ArticleId><ArticleId IdType="pubmed">32170083</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Mo J., Luo X., Zhang G., Liu F., Luo S. (2022). ORFV infection enhances CXCL16 secretion and causes oncolysis of lung cancer cells through immunogenic apoptosis. Front. Cell Infect. Microbiol. 12. doi: 10.3389/fcimb.2022.910466</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.910466</ArticleId><ArticleId IdType="pmc">PMC9358046</ArticleId><ArticleId IdType="pubmed">35959371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Shao X., Gu L., Jiang K., Wang S., Chen J., et al. . (2020. b). Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells. J. Cell Mol. Med. 24 (7), 4286–4297. doi: 10.1111/jcmm.15089</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15089</ArticleId><ArticleId IdType="pmc">PMC7171322</ArticleId><ArticleId IdType="pubmed">32100392</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe D., Goshima F. (2018). Oncolytic virotherapy by HSV. Adv. Exp. Med. Biol. 1045, 63–84. doi: 10.1007/978-981-10-7230-7_4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-10-7230-7_4</ArticleId><ArticleId IdType="pubmed">29896663</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe K., Luo Y., Da T., Guedan S., Ruella M., Scholler J., et al. . (2018). Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight 3 (7), e99573. doi: 10.1172/jci.insight.99573</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.99573</ArticleId><ArticleId IdType="pmc">PMC5928866</ArticleId><ArticleId IdType="pubmed">29618658</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe N., McKenna M. K., Rosewell Shaw A., Suzuki M. (2021). Clinical CAR-T cell and oncolytic virotherapy for cancer treatment. Mol. Ther. 29 (2), 505–520. doi: 10.1016/j.ymthe.2020.10.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.10.023</ArticleId><ArticleId IdType="pmc">PMC7854303</ArticleId><ArticleId IdType="pubmed">33130314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing A., Fajardo C. A., Posey A. D., Jr., Shaw C., Da T., Young R. M., et al. . (2018). Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol. Res. 6 (5), 605–616. doi: 10.1158/2326-6066.Cir-17-0314</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.Cir-17-0314</ArticleId><ArticleId IdType="pmc">PMC6688490</ArticleId><ArticleId IdType="pubmed">29588319</ArticleId></ArticleIdList></Reference><Reference><Citation>Workenhe S. T., Mossman K. L. (2014). Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol. Ther. 22 (2), 251–256. doi: 10.1038/mt.2013.220</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.220</ArticleId><ArticleId IdType="pmc">PMC3916036</ArticleId><ArticleId IdType="pubmed">24048442</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Li Y., Meng Y., Cai X., Shi J., Li J., et al. . (2022). An ion-enhanced oncolytic virus-like nanoparticle for tumor immunotherapy. Angew Chem. Int. Ed Engl. 61 (45), e202210487. doi: 10.1002/anie.202210487</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.202210487</ArticleId><ArticleId IdType="pubmed">36117387</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao J., Liang J., Fan J., Hou P., Li X., Zhang H., et al. . (2022). CDK4/6 inhibition enhances oncolytic virus efficacy by potentiating tumor-selective cell killing and T-cell activation in refractory glioblastoma. Cancer Res. 82 (18), 3359–3374. doi: 10.1158/0008-5472.Can-21-3656</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.Can-21-3656</ArticleId><ArticleId IdType="pubmed">35792620</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie S., Fan W., Yang C., Lei W., Pan H., Tong X., et al. . (2021). Beclin1−armed oncolytic vaccinia virus enhances the therapeutic efficacy of R−CHOP against lymphoma in vitro and in vivo . Oncol. Rep. 45 (3), 987–996. doi: 10.3892/or.2021.7942</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/or.2021.7942</ArticleId><ArticleId IdType="pmc">PMC7860022</ArticleId><ArticleId IdType="pubmed">33469679</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B., Tian L., Chen J., Wang J., Ma R., Dong W., et al. . (2021). An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. Nat. Commun. 12 (1), 5908. doi: 10.1038/s41467-021-26003-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26003-6</ArticleId><ArticleId IdType="pmc">PMC8501058</ArticleId><ArticleId IdType="pubmed">34625564</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Chu L., Yuan S., Yang Y., Yang Y., Xu B., et al. . (2017). RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion. Cell Death Dis. 8 (6), e2835. doi: 10.1038/cddis.2017.230</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2017.230</ArticleId><ArticleId IdType="pmc">PMC5520890</ArticleId><ArticleId IdType="pubmed">28569774</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Hua N., Xie S., Wu Y., Zhu L., Wang S., et al. . (2021). Oncolytic viruses as a promising therapeutic strategy for hematological malignancies. BioMed. Pharmacother. 139, 111573. doi: 10.1016/j.biopha.2021.111573</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.111573</ArticleId><ArticleId IdType="pubmed">33894623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye T., Jiang K., Wei L., Barr M. P., Xu Q., Zhang G., et al. . (2018). Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. Am. J. Cancer Res. 8 (8), 1514–1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6129498</ArticleId><ArticleId IdType="pubmed">30210920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamarin D., Palese P. (2012). Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol. 7, 347–367. doi: 10.2217/fmb.12.4</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.12.4</ArticleId><ArticleId IdType="pmc">PMC4241685</ArticleId><ArticleId IdType="pubmed">22393889</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamarin D., Holmgaard R. B., Subudhi S. K., Park J. S., Mansour M., Palese P., et al. . (2014). Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci. Transl. Med. 6, 226ra232. doi: 10.1126/scitranslmed.3008095</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3008095</ArticleId><ArticleId IdType="pmc">PMC4106918</ArticleId><ArticleId IdType="pubmed">24598590</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Lai W., Li Q., Yu Y., Jin J., Guo W., et al. . (2017). A novel oncolytic adenovirus targeting wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models. Biochem. Biophys. Res. Commun. 491 (2), 469–477. doi: 10.1016/j.bbrc.2017.07.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.07.041</ArticleId><ArticleId IdType="pubmed">28698142</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C. D., Wang Y. L., Zhou D. M., Zhu M. Y., Lv Y., Hao X. Q., et al. . (2021). A recombinant Chinese measles virus vaccine strain rMV-Hu191 inhibits human colorectal cancer growth through inducing autophagy and apoptosis regulating by PI3K/AKT pathway. Transl. Oncol. 14 (7), 101091. doi: 10.1016/j.tranon.2021.101091</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2021.101091</ArticleId><ArticleId IdType="pmc">PMC8063909</ArticleId><ArticleId IdType="pubmed">33848808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z., McGray A. J. R., Jiang W., Lu B., Kalinski P., Guo Z. S. (2022). Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. Mol. Cancer 21 (1), 196. doi: 10.1186/s12943-022-01664-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-022-01664-z</ArticleId><ArticleId IdType="pmc">PMC9554963</ArticleId><ArticleId IdType="pubmed">36221123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>